Granulomatosis with Polyangiitis - Causes, Treatment & When to See a Doctor

```html

What is Granulomatosis with Polyangiitis?

Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, is a rare, autoimmune vasculitis that primarily affects small‑ and medium‑sized blood vessels. The disease causes inflammation in the walls of these vessels, leading to the formation of granulomas—clusters of immune cells that can damage the tissue they infiltrate. GPA most often involves the upper respiratory tract (sinuses and nose), lungs, and kidneys, but it can affect virtually any organ system.

Because the condition can progress rapidly, early recognition and treatment are crucial. According to the Mayo Clinic, the incidence in the United States is roughly 1–3 cases per 100,000 people per year, with a slight male predominance and a peak onset between ages 40–60.

Common Causes

GPA is not caused by an external pathogen; rather, it results from a complex interplay of genetic, environmental, and immune‑system factors. The exact trigger remains unclear, but the following conditions and risk factors are most frequently associated with the disease:

• Genetic susceptibility: Certain HLA‑DQ and HLA‑DR alleles increase risk.
• Autoantibodies (ANCA): Cytoplasmic anti‑neutrophil cytoplasmic antibodies (c‑ANCA) targeting proteinase‑3 (PR3) are present in 80‑90% of patients.
• Infections: Chronic sinusitis, Staphylococcus aureus carriage, and possibly viral infections have been implicated as triggers.
• Medications: Rarely, drugs such as propylthiouracil or hydralazine can induce a GPA‑like vasculitis.
• Silica exposure: Occupational exposure to silica dust has been linked to higher ANCA‑associated vasculitis rates.
• Smoking: Cigarette smoking appears to increase disease severity and relapse risk.
• Environmental pollutants: Airborne particulates may act as adjuvants prompting autoimmune activation.
• Other autoimmune diseases: Patients with rheumatoid arthritis or systemic lupus erythematosus have a modestly increased risk.
• Family history: Although rare, relatives of affected individuals show a slightly higher incidence.
• Age & gender: While not a cause, men in middle age are more frequently diagnosed.

Associated Symptoms

Symptoms vary widely because GPA can involve many organ systems. The classic triad includes upper airway, lung, and kidney involvement, but patients often experience additional systemic manifestations.

• Upper respiratory: Chronic sinusitis, nasal crusting or ulceration, epistaxis, otitis media, and saddle‑nose deformity.
• Lung involvement: Cough (often dry), hemoptysis, shortness of breath, pleuritic chest pain, and diffuse infiltrates on imaging.
• Kidney disease: Hematuria, proteinuria, rapidly progressive glomerulonephritis, and possible renal failure.
• General constitutional: Fever, night sweats, unexplained weight loss, fatigue, and malaise.
• Skin: Palpable purpura, livedo reticularis, ulcerative lesions, or nodules.
• Neurologic: Mononeuritis multiplex, peripheral neuropathy, facial nerve palsy, or CNS vasculitis (rare).
• Ocular: Conjunctivitis, scleritis, or orbital inflammation causing diplopia.
• Joint pain: Arthralgias without true arthritis are common.
• Gastrointestinal: Abdominal pain, gastrointestinal bleeding, or perforation secondary to vasculitis.

When to See a Doctor

Because GPA can rapidly damage organs, any of the following warrant prompt medical evaluation:

• Persistent sinus problems or nosebleeds that do not resolve with standard treatment.
• New or worsening cough, especially if accompanied by blood‑tinged sputum.
• Unexplained or worsening kidney symptoms such as dark urine, swelling of the ankles, or a sudden rise in blood pressure.
• Unexplained fever, night sweats, or weight loss lasting more than two weeks.
• Skin lesions that are rapidly spreading, ulcerating, or painful.
• Sudden loss of sensation or weakness in an arm or leg.
• Any combination of the above symptoms in a person with known ANCA positivity.

Early referral to a rheumatologist, pulmonologist, or nephrologist improves outcomes.

Diagnosis

Diagnosing GPA requires a combination of clinical suspicion, laboratory testing, imaging, and often a tissue biopsy.

Laboratory Tests

• ANCA testing: c‑ANCA (PR3‑ANCA) is positive in ~80–90% of active GPA cases; p‑ANCA (MPO‑ANCA) may be seen in a minority.
• Complete blood count (CBC) – may reveal anemia or leukocytosis.
• Renal function panel – serum creatinine and estimated GFR to evaluate kidney involvement.
• Urinalysis – looks for hematuria, red‑cell casts, and proteinuria.
• Erythrocyte sedimentation rate (ESR) and C‑reactive protein (CRP) – markers of systemic inflammation.

Imaging Studies

• Chest X‑ray: May show nodules, infiltrates, or cavitary lesions.
• High‑resolution CT scan of the chest: Provides detailed view of lung nodules, ground‑glass opacities, and vasculitic changes.
• Sinus CT: Detects mucosal thickening, bone destruction, or granulomatous masses.
• Renal ultrasound: Helps assess kidney size and exclude obstructive causes.

Biopsy

Histopathological confirmation remains the gold standard. Typical findings include necrotizing granulomas, pauci‑immune vasculitis (little or no immune‑complex deposition), and fibrinoid necrosis. Biopsy sites may be:

• Kidney (most definitive for renal involvement).
• Skin lesions.
• Nasopharyngeal tissue.
• Lung tissue via bronchoscopy or video‑assisted thoracic surgery.

Classification Criteria

The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria assign points for ANCA status, biopsy results, and clinical features. A total score ≥5 classifies a patient as having GPA (source: ACR/EULAR 2022).

Treatment Options

Therapy is aimed at inducing remission, preventing organ damage, and maintaining long‑term disease control.

Induction Therapy

Rapidly acting immunosuppressants are used for 3–6 months to bring the disease into remission.

• High‑dose glucocorticoids: Prednisone 1 mg/kg/day (max 60 mg) with taper over weeks.
• Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly ×4 or 1 g two weeks apart). Shown to be non‑inferior to cyclophosphamide and preferred for fertility preservation (source: NEJM 2010).
• Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks) for severe disease, especially with renal involvement.
• Plasma exchange (PLEX): Considered in life‑threatening pulmonary‑renal syndrome (per 2020 PEXIVAS trial, benefit is limited, but still used selectively).

Maintenance Therapy

After remission, lower‑intensity agents are used for ≥12–24 months.

• Azathioprine: 2–2.5 mg/kg/day.
• Mycophenolate mofetil: 1–1.5 g twice daily (alternative for azathioprine intolerance).
• Rituximab: 500 mg every 6 months or 1 g every 6 months, especially in patients with frequent relapses.
• Low‑dose glucocorticoids: <1 mg/kg/day, tapered to ≤5 mg/day as tolerated.

Supportive & Home Care Measures

• Vaccinations: Influenza, pneumococcal, COVID‑19, and hepatitis B (avoid live vaccines while on high‑dose steroids).
• Bone health: Calcium 1,200 mg + vitamin D 800–1,000 IU daily; consider bisphosphonate if on steroids >3 months.
• Infection prophylaxis: Trimethoprim‑sulfamethoxazole (TMP‑SMX) 1 tablet three times weekly reduces risk of Staphylococcus aureus infection and opportunistic Pneumocystis jirovecii pneumonia.
• Smoking cessation and avoidance of silica exposure.
• Regular monitoring of blood counts, liver/kidney function, and ANCA titers.

Prevention Tips

Because GPA is primarily autoimmune, there is no guaranteed way to prevent it. However, the following measures may lower the risk of disease flare or reduce severity:

• Adhere to medication regimens: Skipping doses of immunosuppressants can precipitate relapse.
• Prompt treatment of infections: Early antibiotics for sinus or respiratory infections may reduce immune activation.
• Maintain a healthy lifestyle: Balanced diet, regular exercise, and adequate sleep support immune regulation.
• Avoid known triggers: Discontinue or replace drugs associated with drug‑induced vasculitis (e.g., propylthiouracil).
• Regular follow‑up: Structured visits with a rheumatologist enable early detection of subclinical disease activity.
• Occupational safety: Use protective equipment when working with silica, dust, or chemicals.
• Vaccinate appropriately: Follow immunization guidelines to limit infections that could act as triggers.

Emergency Warning Signs

---

References:

• Mayo Clinic. Granulomatosis with polyangiitis. https://www.mayoclinic.org/
• American College of Rheumatology/European Alliance of Associations for Rheumatology. 2022 Classification Criteria for GPA. PDF
• Yates M, et al. Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine. 2010;363:211–222. doi:10.1056/NEJMoa1209895
• Furuta S, et al. Updated 2021 Guideline for the Management of ANCA-Associated Vasculitis. Kidney International. 2021;100:151–176.
• World Health Organization. WHO Guidelines on the Prevention and Management of Opportunistic Infections in Immunocompromised Hosts. 2022.

```